Elevation Point Wealth Partners LLC Purchases New Shares in Boston Scientific Corporation $BSX

Elevation Point Wealth Partners LLC bought a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 30,795 shares of the medical equipment provider's stock, valued at approximately $1,314,000.

A number of other large investors have also recently modified their holdings of BSX. FWL Investment Management LLC purchased a new stake in Boston Scientific in the second quarter worth about $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $26,000. Sfam LLC purchased a new stake in Boston Scientific in the fourth quarter worth $29,000. Finally, Cresta Advisors Ltd. bought a new position in Boston Scientific in the fourth quarter worth $33,000. Institutional investors own 89.07% of the company's stock.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney bought 186,240 shares of the business's stock in a transaction on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director David C. Habiger purchased 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 194,522 shares of company stock valued at $9,385,210. Company insiders own 0.34% of the company's stock.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $50.39 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The firm has a market cap of $73.03 billion, a price-to-earnings ratio of 20.40, a price-to-earnings-growth ratio of 1.10 and a beta of 0.56. The business has a 50-day simple moving average of $46.34 and a two-hundred day simple moving average of $57.62. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter last year, the firm posted $0.75 EPS. The business's quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has approved a stock buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

BSX has been the topic of a number of research reports. Royal Bank Of Canada dropped their target price on shares of Boston Scientific from $85.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday, July 30th. Wells Fargo & Company lowered their price target on shares of Boston Scientific from $55.00 to $50.00 and set an "equal weight" rating for the company in a research report on Thursday, July 30th. Raymond James Financial reissued an "outperform" rating and set a $57.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Zacks Research cut shares of Boston Scientific from a "hold" rating to a "strong sell" rating in a report on Friday, June 5th. Finally, Needham & Company LLC lowered their target price on shares of Boston Scientific from $77.00 to $57.00 and set a "buy" rating for the company in a report on Wednesday, July 8th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $71.62.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source